Keywords: fda, panel, backs, novo, repaglinide, nordisk, type

FDA Panel Backs Novo's Repaglinide

Article | 27 November 1997

Print This

Novo Nordisk's type 2 diabetes drug Prandin (repaglinide) should beapproved for marketing in the USA, according to the US Food and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in